News|Articles|November 10, 2026

Cariprazine improves mania and depression in pediatric bipolar I

Author(s)Morgan Ebert, Executive Editor

Key Takeaways

In a post hoc analysis of a 52-week open-label study, cariprazine was associated with improvement in both manic and depressive symptoms from week 4 onward in youth aged 10 to 17 years with BPI, whether mania or depression predominated at baseline.
Response, remission, and functional recovery rates generally rose over time but were lower in the depression-predominant subgroup, and discontinuation approached or exceeded 50% in both groups.
Cariprazine's pediatric indication remains limited to acute manic or mixed episodes pending a placebo-controlled bipolar depression trial; monitor for somnolence, weight gain, and akathisia.

Post hoc data show cariprazine improved both manic and depressive symptoms through 52 weeks in youth aged 10 to 17 years with bipolar I disorder.

Cariprazine (VRAYLAR; AbbVie) was associated with early and sustained improvement in both manic and depressive symptoms over 52 weeks in children and adolescents with bipolar I disorder (BPI), regardless of which pole predominated at study entry, according to a post hoc analysis presented at the Neuroscience Education Institute (NEI) Fall Congress in Colorado Springs, Colorado.¹ Significant improvement emerged by week 4 and persisted through week 52 in participants aged 10 to 17 years (P < .0001 at all time points).¹

"Bipolar I disorder in children and adolescents can be particularly challenging to manage because patients may experience a wide range of manic and depressive symptoms that can significantly affect their daily functioning and overall well-being," said Roger S. McIntyre, MD, study author and professor of psychiatry at the University of Toronto, Ontario, Canada. "These findings are encouraging because they suggest that [cariprazine] may help address the full spectrum of manic and depressive symptoms, with statistically significant improvements observed as early as week 4 and sustained through 52 weeks, regardless of which symptoms were predominant at baseline."

Cariprazine post hoc analysis design in pediatric bipolar I disorder

Investigators analyzed data from a 52-week, open-label, flexible-dose, multicenter phase 3 safety study of cariprazine in pediatric BPI (NCT04578756). Mixed-effects models for repeated measures estimated change from baseline on the Young Mania Rating Scale (YMRS) and Children's Depression Rating Scale-Revised (CDRS-R) in a BPI-mania subgroup (baseline YMRS ≥20; n = 43) and a BPI-depression subgroup (baseline CDRS-R ≥45; n = 54).¹ More than half of each subgroup had mixed features at entry (53.5% and 57.4%).¹ Mean modal doses were 3.2 mg/d and 3.0 mg/d, respectively, with mean exposure of about 5 months.¹

Manic and depressive symptom outcomes with cariprazine through week 52

In the BPI-mania subgroup, effect sizes for YMRS improvement were large (Cohen d, 0.81 at week 4 to 0.89 at week 52), and CDRS-R effect sizes were smaller (d, 0.26-0.32). In the BPI-depression subgroup, effect sizes ranged from 0.38 to 0.50 for CDRS-R and 0.28 to 0.37 for YMRS.¹

"Notably, patients experiencing manic symptoms saw improvements in both mania and depression, while those with predominantly depressive symptoms also showed improvements across both symptoms," McIntyre said. "We also observed clinically meaningful rates of response, remission and functional recovery in both groups, which generally increased over the course of the study."

At week 52, the mania subgroup (n = 39) had rates of 69.2% for response (≥50% YMRS reduction), 71.8% for remission (YMRS ≤12), and 48.7% for recovery (remission plus Children's Global Assessment Scale [CGAS] score >70).¹ Corresponding rates in the depression subgroup (n = 51), using CDRS-R thresholds, were 43.1%, 49.0%, and 39.2%.¹

Cariprazine safety and tolerability in youth with bipolar I

Treatment-emergent adverse events (TEAEs) occurred in 62.8% of the mania subgroup and 74.1% of the depression subgroup; serious TEAEs occurred in 2.3% and 3.7%, and 11.6% and 5.6% discontinued because of adverse events.¹ Somnolence and weight gain (18.5% each) were most common in the depression subgroup and nasopharyngitis (11.6%) in the mania subgroup; akathisia occurred in 7.0% and 13.0%.¹

Cariprazine mechanism and current pediatric bipolar I indication

Cariprazine is a dopamine D3-preferring D3/D2 receptor partial agonist and serotonin 5-HT1A receptor partial agonist.¹ It is approved for manic, mixed, and depressive episodes of BPI in adults, and its pediatric approval, granted in December 2025, covers acute manic or mixed episodes in patients 10 years and older.^2-4 It is not approved for pediatric bipolar depression.²

"For pediatric practitioners, these findings highlight why it's so important to look at the full spectrum of symptoms when caring for young patients with bipolar I disorder," McIntyre said. "They also offer encouraging insights into the potential of [cariprazine] to help address the complex, multidimensional nature of this condition."